Letter to the Editor
Bone Marrow Transplantation (2007) 40, 83–84; doi:10.1038/sj.bmt.1705683; published online 23 April 2007
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib
H Menzel1, N von Bubnoff1, A Hochhaus2, C Haferlach3, C Peschel1 and J Duyster1
- 1Third Medical Department, Technical University of Munich, Munich, Germany
- 2Third Medical Department, University Hospital of Mannheim, Mannheim, Germany
- 3Munich Leukemia Laboratory, Munich, Germany
Correspondence: H Menzel, E-mail: H.Menzel@LRZ.TU-Muenchen.de
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Flying under the radar: the new wave of BCR?ABL inhibitors
Nature Reviews Drug Discovery Review (01 Oct 2007)
Getting to the stem of chronic myeloid leukaemia
Nature Reviews Cancer Review (01 May 2008)
Somatic pharmacogenomics in cancer
The Pharmacogenomics Journal Review
Imatinib and beyond?exploring the full potential of targeted therapy for CML
Nature Reviews Clinical Oncology Review (01 Sep 2009)
RESEARCH
Leukemia Letter
